title: [Medium-term effects of intravitreal bevacizumab for macular edema associated with central retinal vein occlusion].
abstract: OBJECTIVE
  To report the medium term effects of intravitreal injection of bevacizumab for central retinal vein occlusion (CRVO) with macular edema.
  
  
  METHODS
  Twenty-two eyes of 22 patients receiving intravitreal injections of 1.25 mg/0.05 ml of bevacizumab (IVB) were included. All patients were followed up for 6 months or longer after the final IVB. The visual acuity and central retinal thickness (CRT) were measured at baseline, one week and every three months after the first IVB.
  
  
  RESULTS
  The mean follow-up after the final IVB was 12.5 months (6-30 months). The mean visual acuity (baseline : 0.63 +/- 0.39) temporarily improved at one week (0.38 +/- 0.33 : p=0.0002), but there was no significant visual improvement at the final visit (0.73 +/- 0.67 : p=1.0). The mean CRT significantly decreased at one week, three months and six months after IVB and at the last visit. There were no differences in either visual or anatomical outcomes between the ischemic type and non-ischemic type.
  
  
  CONCLUSIONS
  Intravitreal injections of bevacizumab should be initially considered as a possible treatment in eyes with macular edema associated with central retinal vein occlusion.
authors: Department of Ophthalmology, Kagawa University Faculty of Medicine, Kagawa, Japan. to3o84@yahoo.co.jp
authors: Aoi
authors: A
authors: Ono
authors: Koki
authors: K
authors: Fukuda
authors: Ayana
authors: A
authors: Yamashita
authors: Chieko
authors: C
authors: Shiragami
authors: Hidetaka
authors: H
authors: Yamaji
authors: Fumio
authors: F
authors: Shiraga